Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1976
No trial phase data available
No trial data available
No trial data available
No approval data available
- University of Arizona researchers discovered that pyrvinium pamoate, an FDA-approved pinworm medication, effectively inhibits Merkel cell carcinoma growth through multiple mechanisms including Wnt pathway modulation. - The drug demonstrated significant tumor regression in mouse models and showed activity against both virus-related and sun damage-related forms of this rare but deadly skin cancer. - With current treatments working for only about half of advanced MCC patients, this repurposed drug offers potential new hope for the approximately 3,000 Americans diagnosed annually with this aggressive cancer.
- A phase 3 trial (SWOG S1815) evaluated the addition of nab-paclitaxel to gemcitabine and cisplatin (GAP) in advanced biliary tract cancer (BTC). - The study found no statistically significant improvement in overall survival (OS) with the GAP regimen compared to gemcitabine and cisplatin (GC) alone. - The GAP regimen was associated with increased toxicity, including hematologic and non-hematologic adverse events, compared to the GC regimen. - Exploratory analyses suggested potential benefits of GAP in specific subgroups, such as locally advanced disease and gallbladder carcinoma, but these were not statistically significant.
